Tirzepatide and Teeth: Dry Mouth, Reflux, and Enamel

"Ozempic teeth" is written across the internet as though the drug dissolves enamel. It does not, and the distinction is not pedantry — it decides what you should actually do about it.

Nothing in tirzepatide's pharmacology acts on tooth structure. There is no dental adverse reaction anywhere in Zepbound's prescribing information: not tooth damage, not caries, not enamel erosion, not tooth loss¹. What exists instead is a set of indirect routes — things the drug genuinely does, which are known dental risk factors in their own right. Acid from reflux. Acid from vomiting. Less saliva. Less fluid.

That is a better position for a patient to be in than "the drug is destroying your teeth," because every one of those routes has something you can do about it. This page separates the four, says which are on the label with a number attached and which are not, and stops where the evidence stops.

What the label actually contains

Start with the document, because most of what gets written on this topic never checks it.

Zepbound's pooled adverse-reaction table from Studies 1 and 2 gives these rates for placebo, 5 mg, 10 mg and 15 mg respectively: vomiting 2%, 8%, 11%, 13%; gastroesophageal reflux disease 2%, 4%, 4%, 5%; nausea 8%, 25%, 29%, 28%; diarrhea 8%, 19%, 21%, 23%¹. Separately, in the same pooled analysis, dry mouth or dry throat was reported by 1% of Zepbound-treated patients versus 0.1% on placebo, and dysgeusia — a change in taste — by 0.4% versus none on placebo¹.

So dry mouth is a real, labeled effect. It is also, at 1%, an uncommon one, which is worth holding onto when the internet implies it is universal.

And there is a fifth item that belongs on this list even though it is filed under kidneys: the label warns about acute kidney injury from volume depletion, noting that the majority of reported events occurred in patients whose gastrointestinal adverse reactions — nausea, vomiting, diarrhea — led to dehydration, and it advises patients to take precautions to avoid fluid depletion¹. Dehydration is the mechanism that connects the gut to the mouth.

Route 1 — reflux

Reflux is the best-evidenced of the four, in both halves of the chain.

The first half is on the label: gastroesophageal reflux disease reached 4–5% on Zepbound against 2% on placebo¹. The mechanism is not mysterious — slowed gastric emptying keeps stomach contents in play for longer, which is covered in tirzepatide, acid reflux and heartburn.

The second half is dentistry's own literature. An overview of ten systematic reviews plus eight additional primary studies concluded that GERD constitutes a risk factor for erosive tooth wear, with a positive association between the two conditions, while noting heterogeneity between studies and a generally low level of evidence³. A separate systematic review and meta-analysis of 71 studies quantified it: digestive disorders carried an odds ratio of 1.81 (95% CI 1.48–2.21) for erosive tooth wear, and the authors' clinical advice was that clinicians screening for erosion risk should concentrate primarily on symptoms of gastroesophageal reflux disease and on dietary factors⁴.

Note what that chain does and does not establish. Tirzepatide raises reflux; reflux is associated with erosion. It does not establish that tirzepatide causes erosion — no study has followed teeth on this drug, or on any GLP-1 drug, over time. It establishes a plausible route with a real risk factor at the end of it.

Route 2 — vomiting

Same shape, higher numbers at the front. Vomiting reached 13% at the 15 mg dose against 2% on placebo¹, and stomach acid reaching teeth is the same intrinsic-acid exposure that makes reflux a risk factor. The dental literature treats both under the same heading of erosive tooth wear from intrinsic acid³⁴.

The practical difference is that vomiting is an event you can respond to, and reflux mostly is not. That matters below.

Route 3 — dry mouth and saliva

Saliva is the mouth's buffer. It neutralizes acid, clears it away, and carries the calcium and phosphate that let enamel remineralize between exposures. Less of it means each acid exposure lasts longer and does more.

The association is documented but weaker than most pages imply. A systematic review of 111 studies of salivary characteristics and tooth wear found a negative association between tooth wear and both salivary pH and flow rate in qualitative synthesis, with meta-analysis of seven studies showing lower stimulated whole-saliva pH in patients with tooth wear (−0.07, 95% CI −0.10 to −0.04). The authors were explicit that risk of bias was mostly unclear, certainty of evidence was low or very low, and no causal association could be observed⁵.

On the tirzepatide side, the drug-to-saliva link is thinner still. Dry mouth is on the label at 1%¹. Beyond that, the direct evidence is case-level: three women taking semaglutide for weight loss presented to an oral medicine clinic with severe dryness and reduced measured salivary flow, which recovered with management ranging from stopping the drug to symptomatic care⁶. Three cases, on a different molecule, with no control group. It is a signal worth reporting and not one to build a claim on — the authors themselves called for larger prospective studies⁶.

Route 4 — what replaces the food

The least-discussed route and one of the more plausible. When appetite collapses and nausea sets in, what people consume changes: more sipping, less chewing, and often a steady all-day trickle of something acidic — sparkling water, electrolyte drinks, lemon water, ginger ale, sugar-free soda — taken specifically because it is the only thing that settles the stomach.

The erosion meta-analysis puts numbers on that category: acidic foods, odds ratio 2.40 (1.44–4.00); carbonated drinks, 1.43 (1.17–1.75); nutritional supplements, 1.73 (1.28–2.35)⁴. None of those studies involved GLP-1 drugs. The relevance is that the drug changes eating patterns toward exactly this list, and the risk factor is the drink, not the prescription.

What is genuinely not established

A 2026 narrative review is the closest thing to an authoritative summary of this whole topic, and it is refreshingly blunt. It names the patient-facing phenomena directly — the cluster of complaints colloquially called "Ozempic mouth," "Ozempic teeth" and "Ozempic breath" — and attributes them to gastrointestinal adverse effects (nausea, vomiting, belching), reduced fluid intake, and possible salivary changes². It files them alongside the facial soft-tissue change people call "Ozempic face," which is instructive: the review treats the whole family as consequences of the drug's known effects and of the weight loss it produces, not as separate pharmacological actions on separate organs². That framing is the same one we apply in what "Ozempic face" actually is.

Its conclusion on the evidence is the sentence most coverage omits: human oral-health-endpoint data remain scarce, and much of the evidence is preclinical, indirect, or derived from case-level or pharmacovigilance reports².

The same review notes the other direction too, which is almost never mentioned: GLP-1 receptors are expressed in oral and craniofacial tissues, and preclinical and limited clinical evidence suggests these drugs may attenuate periodontal inflammation, though effects on alveolar bone remain uncertain². So the class is not straightforwardly bad for the mouth. It is under-studied in the mouth, in both directions, and the review calls for validated oral-health endpoints to be built into future incretin trials².

What to actually do

After vomiting, rinse — do not reach straight for the brush. Water, or a fluoride mouthrinse, clears the acid rather than spreading it across softened enamel. The familiar instruction to then wait thirty minutes before brushing is widely repeated but less settled than it sounds: a 2025 laboratory study cycling enamel specimens through an erosive challenge and simulated brushing found that delaying toothbrushing offered no measurable protective benefit at 0, 15, 30 or 60 minutes, while both fluoridated and CPP-ACP toothpastes did protect enamel hardness compared with brushing with water alone⁷. That is one in-vitro study using an acidic beverage rather than gastric acid, so it does not overturn the advice — it means the toothpaste is doing the work the waiting was credited with. Rinse, then brush with fluoride toothpaste.

Treat the reflux rather than the tooth. If GERD is the route, dental care downstream is damage limitation. Bring it to whoever manages your prescription — reflux is dose-related, and the dose ladder is the first lever.

Hydrate on purpose. The label's own advice on avoiding fluid depletion¹ happens to be the same advice for dry mouth. Water rather than the acidic sipping described above.

Tell your dentist you are on this drug. Both reviews above end at the same place: the dental chair is where these effects present, and the practitioner cannot manage a risk factor they have not been told about²³. Erosion is easy to see early and expensive to fix late.

Do not stop a working drug over this. Nothing above supports that. Rank it against what the drug is doing — see is Zepbound worth it — and against the rest of the ledger in Zepbound side effects.

The honest bottom line

Tirzepatide does not attack enamel, and no dental adverse reaction appears anywhere in its label¹. What it does is raise reflux to 4–5%, vomiting to as much as 13%, dry mouth to 1%, and dehydration risk enough that the label warns about it¹ — and reflux, intrinsic acid and reduced saliva are all documented risk factors for erosive tooth wear, with digestive disorders carrying an odds ratio of 1.81³⁴⁵.

That is a chain of plausible indirect routes, not a demonstrated drug effect on teeth. No study has followed teeth over time in people taking tirzepatide, and the best available review says plainly that human oral-health data are scarce². The useful consequence is that every link in the chain is manageable: rinse after vomiting, brush with fluoride, treat the reflux, drink water rather than something acidic, and tell your dentist.

For the other body changes people ask about during the same weight loss, see tirzepatide and breasts, tirzepatide and body shape, and tirzepatide and your feet. For managing the gut effects that drive all of this, start with tirzepatide and nausea and best tirzepatide.